Q: What is Jobevne used for?

Jobevne is used to treat: metastatic colorectal cancer non-squamous non-small cell lung cancer glioblastoma and others.

Q: How does Jobevne work?

Mechanism of Action Jobevne belongs to a class of medicines called angiogenesis inhibitors. It is designed to interfere with the way tumors grow and spread by targeting their blood supply. The medication works through the following process: Targeting VEGF: Tumors produce a protein called vascular endothelial growth factor (VEGF). This protein sends signals to the body to create new blood vessels that provide the tumor with oxygen and nutrients. Blocking Signals: Jobevne is a monoclonal antibody that specifically binds to the VEGF protein. Inhibiting Growth: By attaching to VEGF, Jobevne prevents the protein from connecting with receptors on the surface of blood vessel cells. This blocks the signal for new blood vessels to form. By limiting the formation of new blood vessels, the medication helps to starve the tumor of the resources it needs to grow and survive.

Q: What are the active ingredients in Jobevne?

The active ingredient in Jobevne is bevacizumab .

Q: What are the side effects of Jobevne?

Common side effects of Jobevne may include: Not FDA approved. No reliable, publicly available data defining common side effects. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Jobevne?

Jobevne belongs to the granulocyte colony-stimulating factor drug class.

Q: What is the dosage of Jobevne and how do I take it?

Administration Jobevne is given as an infusion into a vein (intravenous infusion) by a healthcare professional in a hospital or clinic setting. It is not intended for self-administration. Infusion Schedule The first dose is usually given slowly over a longer period of time. If the first infusion is well-tolerated, subsequent doses may be administered more quickly. The frequency of treatment depends on the specific condition being treated, but it is generally given once every two weeks or once every three weeks. Missed Doses If a scheduled appointment for an infusion is missed, contact your healthcare provider as soon as possible to reschedule the treatment. Maintaining a consistent schedule is important for the effectiveness of the medication.

Q: Is Jobevne safe during pregnancy and breastfeeding?

Pregnancy Jobevne can cause harm to a developing fetus. Based on animal studies and the drug's mechanism of action, it may cause birth defects or pregnancy loss. It is important to discuss pregnancy status with a healthcare provider before starting treatment. Females who are able to become pregnant should use effective contraception during treatment and for 6 months after the final dose. If pregnancy occurs during treatment, the potential risks to the fetus should be discussed with a clinician. Breastfeeding It is not known if Jobevne passes into human breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for 6 months following the last dose. Fertility Jobevne may impair fertility in females. Clinical data indicates that some women may experience ovarian failure while receiving bevacizumab products. It is not certain if these effects on fertility are reversible. Individuals should discuss fertility concerns with their healthcare team before starting this medication.

Q: What is the FDA approval status of Jobevne?

FDA Approval Status Jobevne (bevacizumab-adcd) was approved by the U.S. Food and Drug Administration (FDA) in June 2024. It is a biosimilar to Avastin (bevacizumab), which means it is highly similar to the original biological product with no clinically meaningful differences in safety, purity, or potency. Approved Indications Jobevne is approved for the treatment of several types of cancer, often used in combination with chemotherapy. Its approved uses include: Metastatic colorectal cancer First-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer Recurrent glioblastoma in adults Metastatic renal cell carcinoma Persistent, recurrent, or metastatic cervical cancer Epithelial ovarian, fallopian tube, or primary peritoneal cancer Boxed Warning The FDA-approved labeling for Jobevne includes a boxed warning, the most serious type of warning, for the following risks: Gastrointestinal Perforation: The drug can cause holes to develop in the stomach or intestines, which can be fatal. Surgery and Wound Healing Complications: Jobevne can interfere with the body's ability to heal wounds. It should not be used for at least 28 days before or after elective surgery, and it must be stopped if wound healing complications occur. Hemorrhage: There is an increased risk of severe or fatal bleeding, including coughing up blood or bleeding in the brain. Patients are monitored closely for these complications, and the medication may be permanently discontinued if they occur.

Question 1

What is Jobevne?

Accepted Answer

Jobevne is a biological medication known as a vascular endothelial growth factor (VEGF) inhibitor. It is a monoclonal antibody designed to bind to VEGF, a protein that plays a key role in the formation of new blood vessels.

By targeting and blocking this protein, the medication helps prevent the development of the blood supply that tumors require to grow and spread. This process is intended to slow or stop the progression of certain cancerous growths.

Question 2

What is Jobevne used for?

Accepted Answer

Jobevne is used to treat:

metastatic colorectal cancer
non-squamous non-small cell lung cancer
glioblastoma
and others.

Question 3

How does Jobevne work?

Accepted Answer

Mechanism of Action

Jobevne belongs to a class of medicines called angiogenesis inhibitors. It is designed to interfere with the way tumors grow and spread by targeting their blood supply.

The medication works through the following process:

Targeting VEGF: Tumors produce a protein called vascular endothelial growth factor (VEGF). This protein sends signals to the body to create new blood vessels that provide the tumor with oxygen and nutrients.
Blocking Signals: Jobevne is a monoclonal antibody that specifically binds to the VEGF protein.
Inhibiting Growth: By attaching to VEGF, Jobevne prevents the protein from connecting with receptors on the surface of blood vessel cells. This blocks the signal for new blood vessels to form.

By limiting the formation of new blood vessels, the medication helps to starve the tumor of the resources it needs to grow and survive.

Question 4

What are the active ingredients in Jobevne?

Accepted Answer

The active ingredient in Jobevne is bevacizumab.

Question 5

What are the side effects of Jobevne?

Accepted Answer

Common side effects of Jobevne may include:

Not FDA approved.
No reliable, publicly available data defining common side effects.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Jobevne?

Accepted Answer

Jobevne belongs to the granulocyte colony-stimulating factor drug class.

Question 7

What is the dosage of Jobevne and how do I take it?

Accepted Answer

Administration

Jobevne is given as an infusion into a vein (intravenous infusion) by a healthcare professional in a hospital or clinic setting. It is not intended for self-administration.

Infusion Schedule

The first dose is usually given slowly over a longer period of time. If the first infusion is well-tolerated, subsequent doses may be administered more quickly. The frequency of treatment depends on the specific condition being treated, but it is generally given once every two weeks or once every three weeks.

Missed Doses

If a scheduled appointment for an infusion is missed, contact your healthcare provider as soon as possible to reschedule the treatment. Maintaining a consistent schedule is important for the effectiveness of the medication.

Question 8

Is Jobevne safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Jobevne can cause harm to a developing fetus. Based on animal studies and the drug's mechanism of action, it may cause birth defects or pregnancy loss. It is important to discuss pregnancy status with a healthcare provider before starting treatment.

Females who are able to become pregnant should use effective contraception during treatment and for 6 months after the final dose. If pregnancy occurs during treatment, the potential risks to the fetus should be discussed with a clinician.

Breastfeeding

It is not known if Jobevne passes into human breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for 6 months following the last dose.

Fertility

Jobevne may impair fertility in females. Clinical data indicates that some women may experience ovarian failure while receiving bevacizumab products. It is not certain if these effects on fertility are reversible. Individuals should discuss fertility concerns with their healthcare team before starting this medication.

Question 9

What forms and strengths does Jobevne come in?

Accepted Answer

Jobevne is supplied as a sterile, preservative-free solution. It is available in the following form:

Intravenous Injection: A solution provided in single-dose vials that must be diluted by a healthcare professional before being administered as an infusion into a vein.

Question 10

What is the FDA approval status of Jobevne?

Accepted Answer

FDA Approval Status

Jobevne (bevacizumab-adcd) was approved by the U.S. Food and Drug Administration (FDA) in June 2024. It is a biosimilar to Avastin (bevacizumab), which means it is highly similar to the original biological product with no clinically meaningful differences in safety, purity, or potency.

Approved Indications

Jobevne is approved for the treatment of several types of cancer, often used in combination with chemotherapy. Its approved uses include:

Metastatic colorectal cancer
First-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer
Recurrent glioblastoma in adults
Metastatic renal cell carcinoma
Persistent, recurrent, or metastatic cervical cancer
Epithelial ovarian, fallopian tube, or primary peritoneal cancer

Boxed Warning

The FDA-approved labeling for Jobevne includes a boxed warning, the most serious type of warning, for the following risks:

Gastrointestinal Perforation: The drug can cause holes to develop in the stomach or intestines, which can be fatal.
Surgery and Wound Healing Complications: Jobevne can interfere with the body's ability to heal wounds. It should not be used for at least 28 days before or after elective surgery, and it must be stopped if wound healing complications occur.
Hemorrhage: There is an increased risk of severe or fatal bleeding, including coughing up blood or bleeding in the brain.

Patients are monitored closely for these complications, and the medication may be permanently discontinued if they occur.

Question 11

What should I know about Jobevne and cost?

Accepted Answer

Biosimilar Pricing

Jobevne is a biosimilar to the reference product Avastin. Biosimilars are generally introduced to provide more affordable treatment options for complex biological medications. However, the exact price of Jobevne is not fixed and can vary between different providers and pharmacies.

Factors Influencing Cost

Several variables determine the total out-of-pocket expense for a patient:

Insurance Coverage: Most insurance plans, including Medicare and Medicaid, typically cover bevacizumab products like Jobevne. The specific cost to the patient will depend on their plan's deductible, copayment, or coinsurance requirements.
Dosage Requirements: Jobevne is administered based on the patient's body weight and the specific condition being treated. Larger doses or more frequent treatment cycles will increase the overall cost of therapy.
Administration Fees: Because Jobevne must be administered as an intravenous (IV) infusion by a healthcare professional, patients may be responsible for facility fees and costs associated with the medical staff and equipment used during the procedure.

Patients are encouraged to contact their insurance provider or the financial counselor at their treatment center to obtain a specific cost estimate based on their treatment plan.

Jobevne

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Jobevne

Hospitals.net Disclosure